{
    "nct_id": "NCT04261387",
    "official_title": "A Two-Part (Open-Label Followed by Randomized, Double-Blind, Placebo-Controlled) Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of Topically Administered LUT014 for the Treatment of Radiation-Induced Dermatitis in Breast Cancer Patients",
    "inclusion_criteria": "1. Female subjects diagnosed with stage Tis, T0-T3, N0-N2, M0 Breast Cancer;\n2. Subject is ≥18 years at the time of signing the informed consent form (ICF);\n3. Radiation dermatitis of Grade 2, based on the NCI CTCAE at the Screening and Baseline (D0) visits;\n4. Completed fractionated radiation therapy for breast prior to first dose of study drug (Day 0);\n5. A score of ≥ 6 reported in the Dermatology Life Quality Index at the Screening and Baseline Visits;\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n7. Females of child-bearing potential must have a negative pregnancy test at screening and must agree to use an effective contraception method* or abstain from sex throughout the study until Day 83;\n8. Expected life expectancy greater than 6 months\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Bilateral breast irradiation;\n2. Planned internal mammary node irradiation with electrons. Planned photon coverage of internal mammary chain nodes is acceptable for inclusion in this study;\n3. Planned partial breast accelerated irradiation;\n4. Any cutaneous infection or significant skin disease at Screening or Baseline (Day 0) other than the dermatitis in the area(s) irradiated during fractionated radiation therapy;\n5. T4 breast cancer or direct skin involvement by breast cancer;\n6. Breast implants or underwent breast reconstruction;\n7. Any cancer other than breast cancer within 3 years of Screening, except for carcinoma in situ of the cervix;\n8. Pregnant or lactating;\n9. History of active systemic lupus erythematosus or scleroderma that is believed to increase the risk of developing radiation-induced dermatitis or its severity;\n10. Clinically significant co-morbid diseases\n11. Treatment with a serine/threonine-protein kinase B-Raf (B-Raf) inhibitor, including but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), Braftovi® (encorafenib), and Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer;\n12. Treatment with a topical corticosteroid o the irradiated chest area within 14 days prior to Baseline (Day 0).\n13. Treatment with a systemic corticosteroid within 14 days prior to Baseline (Day 0), except for low dose systemic corticosteroids (e.g., 8-20 mg dexamethasone or comparable) given for up to one or two days every two weeks as part of standard of care for the prevention or treatment of chemotherapy-induced nausea and vomiting (CINV);\n14. Treatment with any investigational drug within 30 days or 5 half-lives of drug prior to Screening, whichever is longer;\n15. Known hypersensitivity to any of the inactive ingredients of the study drug.",
    "miscellaneous_criteria": ""
}